Abu Esba Laila Carolina, Al Mardawi Ghada, Al Mardawi Elham, Almadhi Fay Musaed, Ardah Husam I
King Abdulaziz Medical City, Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.
King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Infect Dis Ther. 2023 Sep;12(9):2259-2268. doi: 10.1007/s40121-023-00865-3. Epub 2023 Sep 13.
Misoprostol is widely used for medication abortion and postpartum hemorrhage. However, it has been associated with the adverse effect of fever, which can pose challenges in management and potentially contribute to unnecessary antibiotic use. The incidence of misoprostol-induced fever in the context of medical abortion has not been extensively studied.
This retrospective cohort study aimed to determine the incidence of fever following misoprostol administration at a tertiary care hospital in Saudi Arabia. The study included female patients who received misoprostol for pregnancy termination or management of missed or incomplete abortion between January 2017 and December 2019. Data on demographics, misoprostol dosage and route, fever characteristics, outcome of abortion, and antibiotic use were collected. Statistical analysis was preformed using appropriate tests.
A total of 213 patients were included in the study. The incidence of fever post-misoprostol administration was 8%. Patients who developed fever had a higher gestational age and received higher doses of misoprostol. However, no significant associations were found between other patient variables and fever incidence. Antibiotic therapy was administered to a almost half of the patients who developed fever post-misoprostol but was determined to be unnecessary in all cases.
This study contributes to the understanding of misoprostol-induced fever in the context of medical abortion. Further research is needed to explore strategies for reducing unnecessary antibiotic use in this population.
米索前列醇广泛用于药物流产和产后出血。然而,它与发热的不良反应有关,这可能给治疗带来挑战,并可能导致不必要的抗生素使用。在药物流产背景下米索前列醇引起发热的发生率尚未得到广泛研究。
这项回顾性队列研究旨在确定沙特阿拉伯一家三级护理医院米索前列醇给药后发热的发生率。该研究纳入了2017年1月至2019年12月期间接受米索前列醇终止妊娠或处理稽留流产或不全流产的女性患者。收集了人口统计学数据、米索前列醇剂量和给药途径、发热特征、流产结局及抗生素使用情况。使用适当的检验进行统计分析。
共有213例患者纳入研究。米索前列醇给药后发热的发生率为8%。发热患者的孕周较大且接受了较高剂量的米索前列醇。然而,未发现其他患者变量与发热发生率之间存在显著关联。近一半米索前列醇给药后发热的患者接受了抗生素治疗,但在所有病例中均确定为不必要。
本研究有助于了解药物流产背景下米索前列醇引起的发热。需要进一步研究以探索减少该人群不必要抗生素使用的策略。